Results 101 to 110 of about 9,643 (207)

Public deliberation to assess patient views on biosimilar medication switching for the treatment of inflammatory bowel disease

BMC Health Services Research
Background Biosimilars are highly similar, but not identical, versions of originator biologic medications. Switching patients to biosimilars presents an opportunity to mitigate rising drug costs and expand patient access to important biologic therapies ...
Kerry A. Ryan, Shirley Cohen-Mekelburg, Jessica A. Baker, Eileen M. Weinheimer-Haus, Chris Krenz, Jason K. Hou, Raymond De Vries, Akbar K. Waljee   +7 more
doaj   +1 more source

miR‐1246 as a Diagnostic, Prognostic, and Therapeutic Biomarker in Breast Cancer: A Narrative Review With Pharmacoeconomic Perspectives

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims MicroRNA‐1246 (miR‐1246) has emerged as an important regulatory molecule in breast cancer, with growing evidence supporting its role in diagnosis, prognosis, and therapeutic response. This review aims to evaluate the diagnostic, prognostic, and therapeutic significance of miR‐1246 in breast cancer and to assess its ...
Abrar Ghaith, Lulu Alsheikh Hussein
wiley   +1 more source

Anti‐PEG Antibodies From mRNA COVID‐19 Vaccines Affect In Vitro Measurements of Pegylated Drug Levels

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The recent adoption of mRNA‐based technology for vaccine development has led to widespread exposure to new vaccine components, such as polyethylene glycol (PEG), against which antibodies may be made. This study assesses the presence of anti‐PEG antibodies in human serum following SARS‐CoV‐2 vaccination, and if these antibodies could interfere ...
Elizaveta A. Svyatova, Zhuoming Liu, Robyn E. Becker, Jungeun M. Sung, Adetunji P. Fayomi, Jeffry A. Florian, James L. Weaver, Rodney Rouse, Kristina E. Howard   +8 more
wiley   +1 more source

Biosimilars and haemophilia [PDF]

Haemophilia, 2018
openaire   +2 more sources

Ten years' clinical experience with biosimilar human growth hormone: a review of efficacy data

Drug Design, Development and Therapy, 2017
Juan Pedro López-Siguero,1 Roland Pfäffle,2 Philippe Chanson,3 Mieczyslaw Szalecki,4,5 Nadja Höbel,6 Markus Zabransky6 1Servicio de Endocrinología Pediátrica, Hospital Materno-Infantil, Hospital Regional Universitario de M&
López-Siguero JP, Pfäffle R, Chanson P, Szalecki M, Höbel N, Zabransky M   +5 more
doaj  

Bridging the Pregnancy Knowledge Gap: A Real‐World Analysis of Medication Use and Drug–Drug Interaction Risk in Crohn's Disease and Multiple Sclerosis

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT The exclusion of pregnant individuals from clinical trials has resulted in a significant medical knowledge gap for this population. Leveraging real‐world data (RWD) provides a critical window into the prevalence and use of medications during pregnancy.
Jacqueline Williams, Rucha Sane, Amita Joshi, Kit Wun Kathy Cheung, Bianca Vora   +4 more
wiley   +1 more source

Translating Asian‐Dominant Pivotal Evidence Into EU Marketing Authorization: An EMA Regulatory Document Analysis, 2021–2025

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT An increasing number of novel molecular entities and biosimilars reach the European Medicines Agency (EMA) supported by pivotal evidence derived predominantly from Asian patient populations. This creates regulatory challenges that the existing ICH E5 framework was not originally designed to address.
Prerona Boruah, Alex Zwiers
wiley   +1 more source

Five‐Year Outcomes and Disease Trajectories in Moderate‐to‐Severe Ulcerative Colitis: A Korean Multicenter Inception Cohort

Journal of Gastroenterology and Hepatology, Volume 41, Issue 8, Page 2338-2348, August 2026.
ABSTRACT Background and Aim The incidence of ulcerative colitis (UC) has been increasing in Asia. Comprehensive data on the long‐term course of moderate‐to‐severe UC remain scarce. This study investigated the clinical outcomes and factors associated with a disabling disease course in Korean patients with moderate‐to‐severe UC.
Byong Duk Ye, Hyo Jong Kim, Dong Il Park, Young Sook Park, Kang‐Moon Lee, Jong Pil Im, Sung‐Ae Jung, Yoon Tae Jeen, Jae Myung Cha, Jae Hee Cheon, Sung Noh Hong, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Chang Kyun Lee   +14 more
wiley   +1 more source

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

Aging Medicine
Objective The primary purpose of this study was to compare the efficacy and safety of proposed biosimilar teriparatide with reference teriparatide in patients of postmenopausal osteoporosis.
Nitin Kapoor, Thomas Paul, Rajeshwar Nath Srivastava, Saurabh Singh, Sunil Maheshwari, Vishal Patil, Awadhesh Kumar Yadav, Girish Bhatia, Sushil H. Mankar, Joe Joseph Cherian, Surabhi Maheshwari, Sudeepti Srivastava, Dattatray Pawar, Roshan Pawar, Amol Aiwale, Amitrajit Pal, Yogesh Rane, Vinayaka Shahavi, Akhilesh Sharma   +18 more
doaj   +1 more source

Biosimilar medicines and cost-effectiveness

ClinicoEconomics and Outcomes Research, 2011
Steven SimoensResearch Centre for Pharmaceutical Care and Pharmaco-economics, Faculty of Pharmaceutical Sciences, Katholieke Universiteit Leuven, Leuven, BelgiumAbstract: Given that biosimilars are agents that are similar but not identical to the ...
Steven Simoens
doaj